Abbott Laboratories Advance New Phase III Trial Drug Targeting MS
Submitted by donna on Wed, 2010-05-26 12:24
Posted Date: 
Wed, 2010-05-26 12:22

Abbott Laboratories [Monday, May 24, 2010], on behalf of Biogen Idec Inc., will advance a new phase 3 trial for a drug candidate targeting multiple sclerosis. The two companies announced Monday that the study’s first patient had been enrolled.

 

Read details of news release.